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Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation
We investigated whether vitreous levels of advanced glycation end products (AGEs) were positively correlated with vascular endothelial growth factor (VEGF) in patients with diabetic retinopathy patients sufficiently treated with retinal photocoagulation. Vitreous AGE and VEGF levels were significantly higher in patients with diabetes than in controls. Positive correlation between AGE and VEGF was found in patients with diabetic retinopathy sufficiently treated with retinal photocoagulation (r = 0.44, p,0.05), but not in those who were insufficiently treated (r = 0.26, p = 0.18). The present observations suggest that AGE may induce VEGF expression in an ischaemia-independent mechanism. AGE could be one of the important determinants of VEGF in diabetic retinopathy without obvious ischaemic regions.
Background
Vascular endothelial growth factor (VEGF) elicits retinal vascular hyperpermeability, thrombosis and angiogenesis, having a central role in the pathogenesis of diabetic retinopathy. 1 Furthermore, vitreous VEGF levels are increased in proliferative diabetic retinopathy, whereas the levels are decreased after treatment with panretinal photocoagulation (PRP). 2 These observations suggest that retinal ischaemia and resultant hypoxia could mainly contribute to VEGF induction in diabetic retinopathy.
Advanced glycation end products (AGEs), senescent macroprotein derivatives formed at an accelerated rate under diabetes, also stimulate VEGF expression in cell cultures and animal models. 3 4 In addition, vitreous AGE levels are positively correlated with VEGF in patients with diabetic retinopathy, suggesting that AGEs may be a stimulant of VEGF in vivo. 5 However, as AGEs predispose the retinal vessels to thrombogenesis, 3 whether AGEs could induce VEGF expression in an ischaemia-independent manner remains unknown. Therefore, in this study, we determined the relationship between vitreous levels of AGEs and VEGF in patients with diabetic retinopathy who were sufficiently treated with PRP for controlling retinal ischaemia.
Patients and methods
The study protocol was approved by our institutional ethics committee, and informed consent was obtained from all patients. Undiluted vitreous samples were collected during vitrectomy from patients with diabetes with a mean (standard deviation (SD)) age of 53 (12.6) years (45 samples from patients with proliferative diabetic retinopathy and 6 from those with diabetic macular oedema). Twenty eight samples from patients without diabetes with a mean (SD) age of 65.3 (6.7) years, having idiopathic macular hole or epiretinal membrane, served as controls. Vitreous levels of AGEs and VEGF were measured as described previously. 5 We classified patients with diabetes into two groups: a sufficiently treated group with PRP (S-PRP; n = 23) and an insufficiently treated group (no or focal retinal coagulation; IS-RP; n = 28), on the basis of the extent of retinal photocoagulation before vitrectomy as described previously. 6 The data were analysed by the Mann-Whitney U test and Spearman's correlation coefficient by rank test.
Results
Vitreous levels of AGEs and VEGF were significantly higher in patients with diabetes than in controls (mean (SD) 0.13 (0.07) v 0.04 (0.03) U and 2.15 (2) v 0.12 (0.23) ng/ml, respectively; p,0.01). As fig 1A and B shows, vitreous VEGF levels were higher in IS-RP than those in S-PRP (2.75 (2.3) v 1.4 (1.3) ng/ml, respectively; p,0.05), whereas there was no significant difference of vitreous levels of AGEs between IS-RP and S-PRP (0.13 (0.07) v 0.13 (0.06) U, respectively). A positive correlation was found between AGEs and VEGF in S-PRP (r = 0.44, p,0.05), but not in IS-RP (r = 0.26, p = 0.18; fig 2 A,B) .
Comment
Our observations suggest that AGEs may induce VEGF expression in an ischaemiaindependent mechanism. In this study, the Postoperative subconjunctival 5-fluorouracil in the management of recurring pterygium
The treatment of choice for pterygium is surgical excision. Recurrence is the most common undesirable treatment outcome. Surgery and other modalities of treatment including b-irradiation, topical thiotepa, intraoperative and postoperative use of mitomycin C, 5-fluorouracil (5-FU) and daunorubicin, have been described to reduce recurrence. [1] [2] [3] [4] [5] [6] [7] [8] [9] Multiple surgery is itself a risk factor for recurrence. 9 We present a case in which the fourth surgery for recurrent pterygium resulted in further recurrence, which was thwarted by multiple intralesional injections of 5-FU. Her unaided visual acuity was 6/9 right eye and 6/6 left eye. The right eye showed a highly vascularised, fleshy nasal pterygium measuring 1168 mm. It had encroached 2.5 mm into the cornea ( fig 1A) . The recurrent pterygium in the right eye was excised for the third time in March 2005. On this occasion, mitomycin C (0.04%) was applied intraoperatively to the scleral bed for 5 min and a double-layered amniotic membrane was grafted to cover the conjunctival defect. A recurrence at the original site was noted 2 months later (fig 1b) , and in an attempt to arrest progression, topical 0.02% mitomycin C was given four times daily for 7 days (three cycles with an interval of 10 days between cycles). The recurrent pterygium, however, progressed to encroach on to the cornea (Fig 1C) . At this point, subconjunctival injections of 5-FU into the advancing lesion, under topical anaesthesia, was started. A 26-gauge needle was used to deposit the injection in the core of the fibrovascular tissue away from the cornea. Over 5 months, she received 10 injections of 5-FU (5 mg in 0.2 ml/injection) given 1-2 weeks apart until the recurrent pterygium became less vascular and atrophic. No complications were noted. Now, 8 months after the last injection, there is no progression (fig 1D) .
Case report

Comment
Pterygium recurrence is thought to be due to fibroblast proliferation and migration and hence use of 5FU, which inhibits fibroblastic activity, is believed to reduce recurrence rates. 5-FU is toxic only to proliferating cells and is considered to be safer than other agents.
10
Postoperative use of 5-FU to halt the progression of recurrence has been described before, but involved a maximum of four injections with a maximum dose of 3 mg.
11 Our patient received 10 injections totalling 50 mg of 5-FU with no complications.
In cases with a high risk of recurrence, such as the one described, intralesional subconjunctival injection of 5-FU even at large doses seems to be safe, effective and well tolerated by the eye. Such an intervention should be considered as an option in the management of difficult cases of recurrent pterygium. 
